The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.
The grant aims to support the discovery and development of medications to combat opioid and psychostimulant use disorders, as well as overdose. It encompasses a two-phase approach: the UG3 phase for initial development with set milestones over two years and the UH3 phase providing three-year funding for projects that achieved their UG3 milestones. This initiative welcomes applications for either preclinical or clinical research studies that promise rapid progress toward FDA approval of effective and safe treatments for opioid use disorders (OUDs) and overdose. Projects may explore new chemical entities, new formulations of existing medications, or combinations of drugs with potential in treating OUDs and overdose. The goal is to expedite the medication discovery process and move potential treatments forward in the FDA's drug development and approval pipeline.